Personal research archive / Beijing / 2026
39.9042° N / 116.4074° E
Living Systems Atlas / INDEX 000
AlexSu
A public field of research, writing, and long-horizon projects across AI, biopharma, economics, and AI–biology pathways toward planetary ecosystem engineering.
AI × BIOLOGY
HUMAN / MACHINE / BIOSPHERE
SPECIMEN / NARCOMEDUSAE
NOAA Ocean Exploration, 2025 Beyond the BlueBiology is not a vertical. It is the operating system of the future.
OPEN PROJECT FIELD / GROWING ARCHIVE
Long-horizon projects
New work enters the field whenever a question proves worth pursuing.
IntelliPharma Insights
Technology-driven essays on AI and biopharma through the lens of philosophy of science—focused on long-term value logic, not individual companies, securities, specific technical solutions, or investment advice.
Economics After AI
Economic reasoning for intelligence, circulation, growth, and social reproduction.
Gaia Project
Synthetic biology, controlled evolution, and engineered planetary habitability.
FIELD NOTE / 01
Life is infrastructure.
Within evolving systems, diverse individuals and environments select one another and co-evolve. Ecosystems can reshape environments—and transform planets.
FIELD / BENTHIC HABITAT
Field Validation of Novel Low-Cost Underwater Robot for Deepwater Exploration and CharacterizationALL PROJECTS / PUBLICATION FEED
Latest updates
No Silver Bullet: The Evolution of Scientific Intelligence in the Real World
Claude Science, slow real-world feedback, cascade control, information gain, and Kauffman’s open phase space offer a framework for thinking about evolving scientific intelligence.
Open entry →
Returning Is the Motion of the Tao. Yielding Is the Way of the Tao.
Starting from China’s innovative-drug licensing wave, quasi-market design, reimbursement reform, and capital-market transition, this essay examines the development stage of Chinese pharma and the capabilities that companies and domestic investors must preserve.
Open entry →
AI Drug Discovery Beyond the Office: How Can It Overcome Capital Imbalance?
Using general-purpose technology theory, the productivity J-curve, and capital appropriability, this essay explains why AI clusters in digitally closed spaces—and how AI drug discovery can cross the capital gap in physically and organizationally open systems.
Open entry →
The Value Logic of AI Drug Discovery Companies
Beginning with the Lilly–Insilico collaboration, this essay explains why the value of an AI drug discovery company cannot be reduced to the success rate of a single pipeline—and how capital sentiment, organizational capability, and long-term technological change shape valuation.
Open entry →
Participating in the Evolution of AI + Pharma
Beginning with the OpenClaw craze, control theory, and China’s open-source history, this essay examines the capital, governance, and technology tensions shaping AI-powered drug discovery.
Open entry →